Today, Sept.1st, the FDA announced its findings regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.
Read Article
Dr. Jack Cush is joined by Drs.
Read Article
Statement from ACR President David Karp, MD, PhD:
Read Article
The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA vac
Read Article
Treatment of RA may be difficult, as it is estimated that up to 10% of patients meet the EULAR definition of difficult-to-treat rheumatoid arthritis (D2T RA). Now a EULAR task force has promulgated several points to consider (PtCs) in managing D2T RA.
Read Article
Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.
Read Article
Tumor necrosis factor inhibitors (TNFi) are frequently used first line in rheumatoid arthritis (RA) patients; and a new analysis shows that repeat use of TNFi dominates over the use of non-TNFi biologics when the initial TNFi therapy has failed.
Read Article
Dr Jack Cush reviews the news, journal articles and FDA warnings from the past week on RheumNow.com
Read Article
Who is the greatest rheumatologist? What makes for a great rheum?
Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring?
Read Article
The current NEJM reports that the use of the Pfizer mRNA vaccine (BNT162b2) demonstrated a very low risk for certain serious adverse events, including the risk of myocarditis (1 to 5 events per 100,000 persons).
Read Article
Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was protective
Read Article
Dr. Jack Cush reviews the news, journal reports and cautions regarding COVID-19
Read Article
Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).
Read Article
Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT) had l
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.
Read Article
Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people.
Read Article
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.
Read Article
Dr. Jack Cush reviews the news, journal articles and more from this past week on RheumNow.com.
Read Article
A prospective study evaluated the value and associations with morning stiffness (MS) in patients with clinically suspect arthralgia (CSA), and found that the presence of MS increases the odds of inflammation (as detected by CRP and MRI synovitis).
Read Article
